iMEAN and New Wave Biotech Partner to Simplify and Accelerate the Path to Scalable Bioprocesses
iMEAN is pleased to announce a strategic partnership with New Wave Biotech, bringing together two complementary areas of expertise to offer biomanufacturers a more direct and reliable path to successful scaleup.
By combining iMEAN’s upstream metabolic modelling and bioprocess simulation capabilities with New Wave Biotech’s downstream optimisation, techno economic analysis (TEA) and life cycle assessment (LCA) toolbox, this collaboration offers one of the first fully integrated digital bioprocess modelling workflows available to the industry.
The goal is simple and effective. Help biomanufacturers take the shorter path to scaleup by giving them science, process and economics visibility from day one.
A Shortcut on the way of the Scalable Bioprocesses
Bioprocess development becomes significantly more efficient when upstream and downstream insights are connected early. Strain design, media optimisation, bioporcess set-up, purification strategy and economic viability all shape each other. When these decisions are aligned, teams gain confidence, clarity and control over their development roadmap.
The iMEAN x New Wave Biotech partnership enables this alignment by combining two modelling strengths into one coherent workflow. Upstream and downstream teams can now work with full visibility, using shared models and scenario simulations to design processes that scale smoothly and economically.
This approach turns bioprocess development from a step by step sequence into a connected, forwardlooking strategy.

What the Combined Platform Makes Possible
With this end-to-end modelling workflow, biomanufacturers can now:
- See feasibility earlier and make confident decisions based on scientific, technical and economic predictions
- Align strain design with downstream requirements to support efficient scaleup
- Optimise culture conditions to enable easier, cleaner and more stable recovery
- Identify and address bottlenecks early before they slow down development
- Boost performance while minimising experimental burden, saving both time and cost
By understanding the whole process from the start, teams can avoid unnecessary iterations and guide their R&D toward conditions that are truly scalable.
A Partnership Built on a Shared Mission
For iMEAN, this partnership reflects a core commitment to deliver tools and expertise that derisk and accelerate bioprocess development.
“The industry talks a lot about digital twins, but the conversation usually stops at the bioreactor. The reality is that the most expensive mistakes in bioprocess development happen when upstream and downstream teams can’t see each other’s constraints — and that’s exactly the gap we’re closing with iMEAN. We have the combined modelling capabilities and the customer results to back it up.” Zoe Yu Tung Law, CEO and Co-Founder, New Wave Biotech
“Metabolic modelling can tell you how to designbuild a better organism and optimise the bioprocess, but it doesn’tcan’t tell you whether beyond this milestone that bioprocessorganism leads to an economic process at scale. Finaly, Ppartnering with New Wave Biotech is a natural extension of our mission at iMEAN, to deliver high-quality, end-to-end services that accelerate and de-risk our customer’R&D. Togehter, we eanble companies to visualise means our customers no longer have to wait until downstream development to discover whether their upstream choices were viable. They can model the full picture from day one.” Rémi Peyraud, CEO and Co-Founder, iMEAN
Both teams share the same belief. Bioprocess design should not rely on late stage trial and error. It should begin with clarity, supported by predictive modelling, economic insight and sustainability foresight.
Who Can Benefit
This combined solution is available immediately and supports biomanufacturers across:
- Precision fermentation and food ingredients
- Industrial biotechnology
- Biobased chemicals
- Cosmetics and personal care
- Pharmaceuticals and therapeutic proteins
- Sustainable materials and new biomolecules
Whether the challenge is early screening, titer improvement, cost reduction or scaleup strategy, this partnership offers a more direct, integrated approach.
Learn More and Start the Conversation
If you would like to explore how this partnership can support your next development cycle or help you accelerate your scaleup roadmap, we would be happy to discuss your project.